Feasible, perhaps not relevant

Urinary infections: Docs say FDA drug trials don't fit U.S. clinical practice

Two companies developing drugs to treat complicated urinary tract infections say it is feasible to conduct trials according to recommendations in FDA's new draft guidance. But clinicians are concerned the results of such studies won't be applicable to real-world clinical practice in the U.S.

A complicated urinary tract infection (cUTI) is characterized by pyuria and pathogen on culture of urine or blood, plus a functional or anatomical abnormality of the urinary tract, and is accompanied by symptoms such as fever, chills and back pain. For a minority of patients, cUTIs can be life threatening due to the risk of septic shock.

cUTI is viewed as an important indication for antibiotic development because it is generally the first indication companies pursue in the Gram-negative space. Gram-negative infections are widely agreed to be the biggest area of unmet need for antibiotics, as these pathogens are growing more and more resistant to existing antibiotic therapies and there are few antibiotics against them in development.

"That is why the emerging resistance is such a problem, because there are very few alternatives," said David Shlaes, president of Anti-Infectives Consulting LLC. Shlaes was previously VP of infectious diseases at Wyeth and EVP of R&D at

Read the full 1966 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers